Merck says it has put aside $48 million in defense funds to battle Fosamax lawsuits that will begin going to trial in 2008.
[Merck CEO Richard] Clark said that the company now faces about 104 cases over Fosamax, the bulk of which have been filed in federal court. He added that the first of these cases will likely not go to trial until 2008. Clark emphasized that Fosamax has been on the market for over 10 years and that reported cases of osteonecrosis were very rare.
Click here to read the concerns of doctors over the longterm safety of the drug. More and more cases of osteonecrosis and other Fosamax side effects are emerging. As with many other things, side effects occur after many years of use.